Payment overview · 2025
General Payments
$854.49
47 reported records · 17 companies
Healthcare provider profile · identity verified
David Locklear, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · MAIDEN, NC · NPI 1679535322
Verified facts
What the public records show
CMS Open Payments records show David Locklear, M.D. received $854.49 in general payments during 2025 across 47 reported records.
Novo Nordisk Inc accounted for 13.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 24 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Farxiga, Gemtesa, Jardiance, Mounjaro, Ozempic, Rybelsus, Trelegy Ellipta, Wegovy.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 43 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 39 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Symbicort by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 33 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 33 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 67 claims for Mounjaro by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 100 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Rybelsus by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Wegovy as an associated drug or biological on 183056 records involving 75256 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Wegovy by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 68 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Paxlovid by this doctor in 2024.
Sumitomo Pharma America, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported GEMTESA as an associated drug or biological on 61692 records involving 22152 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Gemtesa by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $118.31 | 13.8% | 7 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $116.25 | 13.6% | 7 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $104.17 | 12.2% | 6 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $89.95 | 10.5% | 4 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $88.32 | 10.3% | 4 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $50.48 | 5.9% | 2 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $49.60 | 5.8% | 2 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $37.33 | 4.4% | 3 | 2025 |
| Verona Pharma, Inc. | Unresolved — no canonical attribution shown | $36.59 | 4.3% | 2 | 2025 |
| TOLMAR, INC. | Unresolved — no canonical attribution shown | $29.13 | 3.4% | 2 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $28.39 | 3.3% | 2 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $25.34 | 3.0% | 1 | 2025 |
| Edwards Lifesciences Corporation | Unresolved — no canonical attribution shown | $17.99 | 2.1% | 1 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $16.91 | 2.0% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $16.48 | 1.9% | 1 | 2025 |
| Viatris Specialty LLC | Unresolved — no canonical attribution shown | $15.65 | 1.8% | 1 | 2025 |
| Kowa Pharmaceuticals America, Inc. | Unresolved — no canonical attribution shown | $13.60 | 1.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $854.49 | 47 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $89.95 | 4 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $88.32 | 4 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $86.95 | 5 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $86.39 | 5 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $66.85 | 4 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $66.79 | 3 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $61.16 | 4 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $51.29 | 3 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $50.48 | 2 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $50.48 | 2 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $49.60 | 2 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $46.34 | 3 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $43.01 | 2 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $37.33 | 3 | 2025 |
Source payment records
|
|||||
| Ohtuvayre Normalized: ohtuvayre |
Drug | Verona Pharma, Inc. | $36.59 | 2 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $31.36 | 2 | 2025 |
Source payment records
|
|||||
| JATENZO Normalized: jatenzo |
Drug | TOLMAR, INC. | $29.13 | 2 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $28.39 | 2 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $25.34 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $21.53 | 1 | 2025 |
Source payment records
|
|||||
| Edwards SAPIEN 3 Ultra Transcatheter Heart Valve Normalized: edwards sapien 3 ultra transcatheter heart valve |
Device | Edwards Lifesciences Corporation | $17.99 | 1 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $16.91 | 1 | 2025 |
Source payment records
|
|||||
| YUPELRI Normalized: yupelri |
Drug | Viatris Specialty LLC | $15.65 | 1 | 2025 |
Source payment records
|
|||||
| ZORYVE Normalized: zoryve |
Drug | Kowa Pharmaceuticals America, Inc. | $13.60 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 68 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 39 | exact normalized | Medicare Part D |
| GEMTESA gemtesa |
2025 | Gemtesa | 2024 | 19 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 33 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 67 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 100 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 24 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 26 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Wegovy wegovy |
2025 | Wegovy | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
43 | 12 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
39 | 13 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
33 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
26 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
33 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
67 | 14 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
100 | 16 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Wegovy open payments reported associated product |
CMS Open Payments — General Payments 183056 supporting records · 75256 recipient NPIs · example record 1188130070 |
Wegovy · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
68 | 15 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
16 | 16 |
| Sumitomo Pharma America, Inc. Exact reporting entity; no affiliate inference |
2025 | GEMTESA open payments reported associated product |
CMS Open Payments — General Payments 61692 supporting records · 22152 recipient NPIs · example record 1176593503 |
Gemtesa · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 441 | 116 |
| Levothyroxine Sodium | Levothyroxine Sodium | 431 | 119 |
| Amlodipine Besylate | Amlodipine Besylate | 361 | 100 |
| Omeprazole | Omeprazole | 292 | 81 |
| Lisinopril | Lisinopril | 268 | 74 |
| Losartan Potassium | Losartan Potassium | 265 | 71 |
| Pantoprazole Sodium | Pantoprazole Sodium | 254 | 70 |
| Meloxicam | Meloxicam | 249 | 72 |
| Metformin Hcl | Metformin Hcl | 238 | 63 |
| Pioglitazone Hcl | Pioglitazone Hcl | 224 | 47 |
| Gabapentin | Gabapentin | 223 | 54 |
| Trazodone Hcl | Trazodone Hcl | 208 | 45 |
| Tamsulosin Hcl | Tamsulosin Hcl | 187 | 47 |
| Montelukast Sodium | Montelukast Sodium | 159 | 40 |
| Tramadol Hcl | Tramadol Hcl | 159 | 40 |
| Glimepiride | Glimepiride | 158 | 32 |
| Alprazolam | Alprazolam | 132 | 32 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 127 | 43 |
| Zolpidem Tartrate | Zolpidem Tartrate | 109 | 25 |
| Simvastatin | Simvastatin | 108 | 30 |
| Metoprolol Succinate | Metoprolol Succinate | 107 | 36 |
| Escitalopram Oxalate | Escitalopram Oxalate | 105 | 26 |
| Quetiapine Fumarate | Quetiapine Fumarate | 105 | 19 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 100 | 28 |
| Ozempic | Semaglutide | 100 | 16 |
| Allopurinol | Allopurinol | 96 | 30 |
| Hydrochlorothiazide | Hydrochlorothiazide | 94 | 29 |
| Sertraline Hcl | Sertraline Hcl | 94 | 25 |
| Metoprolol Tartrate | Metoprolol Tartrate | 92 | 22 |
| Carvedilol | Carvedilol | 86 | 23 |
| Tizanidine Hcl | Tizanidine Hcl | 86 | 19 |
| Metformin Hcl Er | Metformin Hcl | 85 | 28 |
| Famotidine | Famotidine | 84 | 23 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 84 | 17 |
| Clonazepam | Clonazepam | 82 | 16 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 82 | 23 |
| Furosemide | Furosemide | 81 | 30 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 79 | 24 |
| Diclofenac Sodium | Diclofenac Sodium | 77 | 20 |
| Amoxicillin | Amoxicillin | 75 | 66 |
| Fluoxetine Hcl | Fluoxetine Hcl | 75 | 20 |
| Duloxetine Hcl | Duloxetine Hcl | 74 | 15 |
| Pravastatin Sodium | Pravastatin Sodium | 71 | 21 |
| Atenolol | Atenolol | 68 | 21 |
| Eliquis | Apixaban | 68 | 15 |
| Mounjaro | Tirzepatide | 67 | 14 |
| Fluticasone Propionate | Fluticasone Propionate | 64 | 21 |
| Lorazepam | Lorazepam | 62 | 18 |
| Potassium Chloride | Potassium Chloride | 61 | 14 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 55 | 12 |
| Buspirone Hcl | Buspirone Hcl | 53 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 53 | 18 |
| Prednisone | Prednisone | 49 | 31 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 48 | 13 |
| Azithromycin | Azithromycin | 48 | 42 |
| Ezetimibe | Ezetimibe | 48 | 14 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 47 | 22 |
| Bupropion Xl | Bupropion Hcl | 47 | 12 |
| Celecoxib | Celecoxib | 46 | 14 |
| Clopidogrel | Clopidogrel Bisulfate | 46 | 13 |
| Fenofibrate | Fenofibrate | 44 | 12 |
| Synthroid | Levothyroxine Sodium | 43 | 12 |
| Telmisartan | Telmisartan | 43 | 13 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 43 | 13 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 42 | 13 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 42 | 28 |
| Citalopram Hbr | Citalopram Hydrobromide | 41 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 40 | 11 |
| Pregabalin | Pregabalin | 40 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 39 | 13 |
| Warfarin Sodium | Warfarin Sodium | 38 | suppressed |
| Aripiprazole | Aripiprazole | 37 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 36 | suppressed |
| Fluconazole | Fluconazole | 35 | 19 |
| Memantine Hcl | Memantine Hcl | 35 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 34 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 34 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 34 | suppressed |
| Jardiance | Empagliflozin | 33 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 33 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 32 | suppressed |
| Methylprednisolone | Methylprednisolone | 32 | 28 |
| Ondansetron Hcl | Ondansetron Hcl | 31 | 11 |
| Alendronate Sodium | Alendronate Sodium | 30 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 30 | suppressed |
| Baclofen | Baclofen | 29 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 29 | 24 |
| Ibandronate Sodium | Ibandronate Sodium | 29 | suppressed |
| Estradiol | Estradiol | 28 | suppressed |
| Finasteride | Finasteride | 28 | suppressed |
| Cefdinir | Cefdinir | 26 | 21 |
| Lamotrigine | Lamotrigine | 26 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 26 | suppressed |
| Eszopiclone | Eszopiclone | 25 | suppressed |
| Mirtazapine | Mirtazapine | 25 | 11 |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 24 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 24 | suppressed |
| Ibuprofen | Ibuprofen | 24 | suppressed |
| Olanzapine | Olanzapine | 24 | suppressed |
| Ondansetron Odt | Ondansetron | 24 | 14 |
| Rybelsus | Semaglutide | 24 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 22 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 21 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 21 | suppressed |
| Mupirocin | Mupirocin | 21 | 11 |
| Topiramate | Topiramate | 21 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 20 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 20 | suppressed |
| Gemtesa | Vibegron | 19 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 19 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 19 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 18 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 17 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 17 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 16 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 16 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 16 | suppressed |
| Glipizide Er | Glipizide | 16 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 16 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 16 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 16 | 16 |
| Temazepam | Temazepam | 16 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 16 | suppressed |
| Calcitriol | Calcitriol | 15 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 15 | 11 |
| Solifenacin Succinate | Solifenacin Succinate | 15 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 15 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 15 | suppressed |
| Chlorthalidone | Chlorthalidone | 14 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 14 | suppressed |
| Telmisartan-Hydrochlorothiazid | Telmisartan/Hydrochlorothiazid | 14 | suppressed |
| Trimethoprim | Trimethoprim | 14 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 14 | suppressed |
| Acyclovir | Acyclovir | 13 | suppressed |
| Cephalexin | Cephalexin | 13 | suppressed |
| Januvia | Sitagliptin Phosphate | 13 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 13 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 12 | suppressed |
| Icosapent Ethyl | Icosapent Ethyl | 12 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 12 | 11 |
| Primidone | Primidone | 12 | suppressed |
| Ramipril | Ramipril | 12 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 12 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 11 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 11 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 11 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 11 | suppressed |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 11 | suppressed |
| Humulin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 11 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 11 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 11 | suppressed |
| Nitroglycerin | Nitroglycerin | 11 | suppressed |
| Selegiline Hcl | Selegiline Hcl | 11 | suppressed |
| Valsartan | Valsartan | 11 | suppressed |
| Wegovy | Semaglutide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $854.49 · 47 records | Novo Nordisk Inc | AREXVY, BREZTRI, CAPLYTA, Dexcom G6 Transmitter, ELIQUIS, Edwards SAPIEN 3 Ultra Transcatheter Heart Valve, FARXIGA, FREESTYLE LIBRE 3, GEMTESA, JARDIANCE, JATENZO, MOUNJARO, NURTEC ODT, Ohtuvayre, Ozempic, Rybelsus, TRELEGY ELLIPTA, VOQUEZNA, VRAYLAR, Wegovy, YUPELRI, ZAVZPRET, ZEPBOUND, ZORYVE | 13 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error